Biomm S.A. (BIOM3)
B3 B3 Primary Summary
Biomm S.A. (BIOM3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomm S.A. ever had a stock split?
Biomm S.A. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Heraldo Carvalho Marchezini CEO | B3 Exchange | BRBIOMACNOR2 ISIN |
| Brazil Country | 130 Employees | - Last Dividend | 21 Mar 2013 Last Split | - IPO Date |
Overview
Biomm S.A. is a prominent biotechnology company based in Nova Lima, Brazil. Since its establishment in 2001, the company has been at the forefront of biotechnological advancements in Brazil, focusing on the development and commercialization of a diverse range of biopharmaceutical products. Their offerings are particularly notable in the realms of diabetes management and cancer treatment, representing significant contributions to healthcare solutions in these areas.
Products and Services
- AFREZZA
A revolutionary human insulin inhalation powder designed for the treatment of diabetes. AFREZZA offers a novel mode of insulin delivery, distinguishing itself from traditional subcutaneous injection methods.
- GHEMAXAN
An enoxaparina sodica based product, GHEMAXAN is formulated for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It acts as an anticoagulant, reducing the risk of forming dangerous blood clots.
- GLARGILIN
A glargine insulin solution, GLARGILIN is utilized in the management of diabetes mellitus. Its long-acting formula helps in maintaining stable blood glucose levels over extended periods, making it an essential tool for individuals managing their diabetes.
- WOSULIN R
WOSULIN R is a formulation of human insulin designed for rapid action, thereby assisting in the control of blood sugar levels immediately after meals, making it an integral part of diabetes management regimens.
- WOSULIN N
This is an isophane insulin product, known for its intermediate duration of action. WOSULIN N is used in the steadying of blood glucose levels throughout the day, providing a balanced approach to insulin therapy.
- HERZUMA
A biosimilar of trastuzumab, HERZUMA is utilized in the treatment of certain HER2-positive breast cancers. Its formulation aims to target and disrupt the growth of cancer cells, offering a targeted therapeutic option.
- CANETA LIFEPEN G PARA APLICACAO DE INSULINA
A specialized insulin application pen designed to facilitate the administration of insulin. The CANETA LIFEPEN G enhances the ease and precision of insulin dosing, catering to the needs of individuals dependent on insulin injections for diabetes management.
Contact Information
